Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma
IntroductionEvaluating predictive biomarkers early in treatment, clinicians can anticipate Q7 77 78 survival outcomes. Ferritin has emerged as a promising predictor of clinical 79 outcomes in multiple myeloma (MM) patients undergoing chimeric antigen patient responses and tailor therapeutic strategi...
Saved in:
| Main Authors: | Eider F. Moreno-Cortes, Mariano Arribas, David A. Martinez-Gamboa, Juana Figueroa-Aguirre, Rohan Patel, Daniel Bihnam, Udit Yadav, J. Erin Wiedmeier-Nutor, Leif Bergsagel, Saurabh Chhabra, Rafael Fonseca, Januario E. Castro |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Hematology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1618331/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cellular therapies in rheumatic and musculoskeletal diseases
by: Pedro Franco-Fuquen, et al.
Published: (2025-06-01) -
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
by: Lili Zhou, et al.
Published: (2025-05-01) -
Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece
by: Eleni Gavriilaki, et al.
Published: (2025-05-01) -
Encadenamiento de desplazamientos: el transporte público de Santiago como productor de actividad comercial
by: Alejandro Cortés Salinas, et al.
Published: (2012-11-01) -
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
by: Januario E. Castro, et al.
Published: (2022-01-01)